Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07488949
Recruiting Not applicable

Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

NCT07488949 · tracked via the Priya Life Science China tracker
Sponsor
Fang Wang
Phase
Not applicable
Started
2024-04-09
Last updated
2026-03-23

Condition(s) studied

Chronic Endometritis

Investigational drug(s) / intervention(s)

Doxycycline combined with Medroxyprogesterone →Doxycycline combined with placebo

Doxycycline combined with Medroxyprogesterone: doxycycline 200 mg/day (100 mg twice daily) combined with medroxyprogesterone acetate(MPA) 24 mg/day (8 mg three times daily) for 14 days

Doxycycline combined with placebo: doxycycline 200 mg/day (100 mg twice daily) with placebo 24 mg/day (8 mg three times daily) for 14 days

Study summary

A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * women aged 20-45 years; * plans to conceive within 12 months; * chronic endometritis(CE) confirmed by endometrial CD138 immunohistochemistry (IHC); * a diagnosis of recurrent reproductive failure(RRF); * willingness to undergo hysteroscopy and endometrial biopsy; * no contraindications to the study medications. Exclusion Criteria: * acute genital tract infection, gynecologic malignancy, endometrial hyperplasia, or uterine fibroids; * pregnancy or lactation; * contraindications to hysteroscopy or anesthesia; * use of antibiotics, glucocorticoids, estrogens, or progestins within 3 months before trial initiation; * allergy to doxycycline or medroxyprogesterone acetate(MPA); * abnormal semen parameters in the male partner.

Primary outcome measure(s)

  • Cure rate of chronic endometritis — At 8 weeks after completion of treatment

Trial sites (1)

FacilityCityRegionStatus
Lanzhou University Second Hospital Lanzhou Gansu Recruiting

More Fang Wang trials in China

Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia Starting soon

Other trials for the same condition

Randomized Controlled Trial of Berberine in Combination With Doxycycline in the Treatment of Chronic Endometritis Recruiting
FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07488949 on ClinicalTrials.gov ↗ ← All trials in China